Beam Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

BEAM$25.15-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
License and collaboration revenue	$490	$8,466	$32,228	$15,936
Operating expenses:
Research and development	95,096	101,758	199,620	200,574
General and administrative	31,947	26,859	66,376	54,799
Total operating expenses	127,043	128,617	265,996	255,373
Loss from operations	(126,553)	(120,151)	(233,768)	(239,437)
Other income (expense):
Change in fair value of derivative liabilities	(4,200)	1,300	(1,700)	4,500
Change in fair value of non-controlling equity investments	338	4,415	354	2,334
Change in fair value of contingent consideration liabilities	(205)	(28)	309	(55)
Gain on sale of equity method investment	455	—	455	—
Interest and other income (expense), net	7,487	12,326	17,354	22,190
Total other income (expense)	3,875	18,013	16,772	28,969
Net loss	$(122,678)	$(102,138)	$(216,996)	$(210,468)
Unrealized gain (loss) on marketable securities	(1,119)	(150)	(3,300)	(669)
Comprehensive loss	$(123,797)	$(102,288)	$(220,296)	$(211,137)
Net loss per common share, basic and diluted	$(1.18)	$(1.00)	$(2.09)	$(2.21)
Weighted-average common shares outstanding, basic and diluted	104,326,669	101,995,184	103,797,276	95,023,977

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.